Pharmaceutical Research

, Volume 14, Issue 4, pp 522–526 | Cite as

Interactions of Aldosterone Antagonist Diuretics with Human Serum Proteins

  • Norito Takamura
  • Toru Maruyama
  • Shamim Ahmed
  • Ayaka Suenaga
  • Masaki OtagiriEmail author


Purpose. The purpose of this study was to investigate the binding mechanism of aldosterone antagonist diuretics with human serum proteins, human serum albumin (HSA) and α1-acid glycoprotein (AGP), as well as to identify the binding sites of the drugs on these proteins.

Methods. Binding activities of spironolactone (SP) and its pharmacologically active metabolite canrenone (CR) to serum and serum protein were examined by ultrafiltration and spectroscopic techniques. The data for the binding of these drugs to HSA were analyzed on the basis of a theoretical model of simultaneous binding of the ligands.

Results. The binding percentages of antagonist diuretics SP and CR to human serum proteins were 88.0% and 99.2%, respectively, at therapeutic concentrations. SP bound strongly and almost equally to both HSA and AGP, but CR bound strongly only to HSA. In addition, the displacement results found using fluorescent probes and ultrafiltration methods demonstrated that SP bound to site I, particularly to the warfarin region on HSA, and to the basic binding site on AGP, while CR bound to the warfarin region on HSA.

Conclusions. The limited results presented here stress the need for caution on coadministration of acidic drugs which bind to the warfarin region on HSA and basic drugs which bind to AGP with SP and its metabolite CR.

spironolactone canrenone drug interaction human serum albumin α1-acid glycoprotein 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W. P. M. H. Overdiek, W. A. J. J. Hermens, and F. W. H. M. Merkus. New insights into the pharmacokinetics of spironolactone. Clin. Pharmacol. 38:469–474 (1985).Google Scholar
  2. 2.
    G. Sudlow, D. J. Birkett, and D. N. Wade. Further characterization of two specific binding sites on human serum albumin. Mol. Pharmacol. 12:1052–1061 (1976).Google Scholar
  3. 3.
    G. Scatchard. Attractions of proteins for small molecules and ions. Ann. NY. Acad. Sci. 51:660–672 (1949).Google Scholar
  4. 4.
    K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4:879–885 (1981).Google Scholar
  5. 5.
    U. Kragh-Hansen. Molecular aspects of ligand binding to serum albumin. Pharmacol. Rev. 33:17–53 (1981).Google Scholar
  6. 6.
    M. O. Decroix, R. Zini, J. C. Chaumeil, and J. P. Tillement. Cefazolin serum protein binding and its inhibition by billirubin, fatty acids and other drugs. Biochem. Pharmacol. 37:2807–2814 (1988).Google Scholar
  7. 7.
    S. N. Anthony, B. K. Ronald, and W. N. David. Distribution coefficients and in vitro human serum protein binding of spironolactone and its 7α-carboxymethyl analog. J. Pharm. Sci. 69:30–32 (1980).Google Scholar
  8. 8.
    K. J. Fehske, W. E. Muller, and U. Wollert. The location of drug binding sites in human serum albumin. Biochem. Pharmacol. 30:687–692 (1981).Google Scholar
  9. 9.
    K. Yamasaki, T. Maruyama, U. Kragh-Hansen, and M. Otagiri. Characterization of site I on human serum albumin: concept about the structure of a drug binding site. Biochim. Biophys. Acta 1295:147–157 (1996).Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • Norito Takamura
    • 1
    • 2
  • Toru Maruyama
    • 1
  • Shamim Ahmed
    • 1
  • Ayaka Suenaga
    • 1
  • Masaki Otagiri
    • 1
    Email author
  1. 1.Department of Pharmaceutics, Faculty of Pharmaceutical SciencesKumamoto UniversityKymamotoJapan.
  2. 2.Department of PharmacyMiyazaki Medical College HospitalKiyo-takecho, Miyazaki-gum, MiyazakiJapan

Personalised recommendations